Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/28/23
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline ProgressBusiness Wire • 03/28/23
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023Business Wire • 03/07/23
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic FibrosisBusiness Wire • 01/31/23
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/19/22
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus TherapeuticsPRNewsWire • 12/12/22
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline ProgressBusiness Wire • 11/09/22
Arcturus Therapeutics to Present at the Following Investor Conferences in NovemberBusiness Wire • 11/07/22
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?Zacks Investment Research • 11/04/22
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA VaccinesBusiness Wire • 11/01/22
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine TechnologyPRNewsWire • 11/01/22
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022Business Wire • 10/26/22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza ResponseBusiness Wire • 08/31/22
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 VaccineBusiness Wire • 08/18/22